Ashok Bhatt

Ashok Bhatt leads synthetic lethality-based oncology drug discovery at Pfizer, advancing novel synthetic lethal targets beyond PARP/BRCA into the clinic. His work encompasses WEE1 inhibitors, ATR inhibitors, and other DNA damage response agents targeting tumors with specific genomic vulnerabilities. He has contributed to the design of biomarker-driven clinical trials that exploit synthetic lethal relationships in patient populations selected by mutation status. His industry perspective complements academic work in translating synthetic lethality discoveries into approved cancer medicines.